67319-04-4

Usage

Uses

Used in Epoxy Resin Industry:
1-Ethoxymethyl-1H-imidazole is utilized as a reactive diluent in certain epoxy resins, enhancing their performance and processing characteristics.
Used in Adhesive and Coating Industry:
In the adhesive and coating sector, 1-Ethoxymethyl-1H-imidazole serves as a curing agent for epoxy adhesives and coatings, improving their curing properties and end-use performance.
Used in Pharmaceutical Industry:
1-Ethoxymethyl-1H-imidazole is employed as a building block in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents.
These applications highlight the compound's multifaceted utility across different industries, underscoring its importance in material science and pharmaceutical development.

Upstream product

• 288-32-4 1H-imidazole 
• 3188-13-4 ethyl chloromethyl ether 
• 64632-25-3 ethoxymethyl triethylammonium chloride 
• 50-00-0 formaldehyd 
• 762-04-9 phosphonic acid diethyl ester 

Downstream Products

• 140477-03-8 1-Dodecyloxymethoxy-dodecane 
• 118179-06-9 1-Dodecyloxymethyl-3-ethoxymethyl-3H-imidazol-1-ium; chloride 
• 91508-79-1 1-Hexadecyloxymethoxy-hexadecane 
• 118179-08-1 3-Ethoxymethyl-1-hexadecyloxymethyl-3H-imidazol-1-ium; chloride 
• 2568-90-3 di-n-butyloxymethane 
• 118178-99-7 1-Butoxymethyl-3-ethoxymethyl-3H-imidazol-1-ium; chloride 
• 54815-12-2 bis(hexyloxy)methane 
• 118179-01-4 3-Ethoxymethyl-1-hexyloxymethyl-3H-imidazol-1-ium; chloride 
• 1262764-64-6 3-ethoxymethyl-1-(1R,2S,5R)-(-)-menthoxymethylimidazolium chloride 
• 850429-55-9 2-chloro-1-(ethoxymethyl)-1H-imidazole 

Relevant academic research and scientific papers

Preparation method of tripod-type ligand for single-molecule magnets

The present invention relates to a preparation method of a tripod-type ligand for single-molecule magnets, and provides a tripod ligand for synthesizing a single-molecule magnet. According to the present invention, the ligand can make the single-molecule magnet exhibit good magnetism at a low temperature so as to be further used for magnetic devices; and the synthesis method has advantages of simple process, low cost, good repeatability, and the like.

Regioselective electrophilic fluorination of rationally designed imidazole derivatives

We report the regioselective and direct functionalization of rationally designed imidazole derivatives through electrophilic fluorination with N-fluorobenzenesulfonimide enabled via in situ deprotonation with lithium 2,2,6,6-tetramethylpiperidine. Aided b

N-Alkoxymethylation of heterocyclic compounds with diethyl phosphite via cleavage of P-O bond

N-Alkoxymethylation of heterocyclic compounds with diethyl phosphite via cleavage of P-O bond was investigated and a series of N3-ethoxymethylated heterocyclic compounds were synthesized. A mechanism in which diethyl phosphite acts as an efficient surrogate of ethanol was proposed and supported by several evidences.

3-Alkoxymethyl-1-(1R,2S,5R)-(-)-menthoxymethylimidazolium salts-based chiral ionic liquids

A new group of imidazolium salt-based chiral ionic liquids have been prepared and characterized. The chiral ionic liquids obtained are stable in air, in contact with water and popular organic solvents. Their physicochemical properties, single-crystal X-ray structures, antimicrobial activities, and antielectrostatic effects have been determined. The chiral ionic liquids synthesized have proven to represent not only potential new solvents in asymmetric synthesis but also effective disinfectants with antielectrostatic activity.

Compounds for treating tumors

The invention provides compounds of formula (I): wherein E, A, B′, R6, R7, R8, and R9 are defined in the specification which compounds exhibit anticancer activity and are useful for treating cancer.

Substituted phenyl farnesyltransferase inhibitors

Compounds of formula (I) or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

Quaternary ammonium compounds as tachykinin antagonists

The present invention provides a compound of formula (I) wherein R is phenyl, C3-C7cycloalkyl or heteroaryl, each of which being optionally benzo- or C3-C7cycloalkyl-fused and optionally substituted, including in the benzo- or C3-C7cycloalkyl-fused portion, by from 1 to 3 substituents each independently selected from C1-C4alkyl, fluoro(C1-C4)alkyl, C1-C4alkoxy, fluoro(C1-C4)alkoxy, phenoxy, C2-C4alkanoyl, halo, C1-C4alkoxycarbonyl, C3-C7cycloalkyl, —S(O)m(C1-C4alkyl), cyano, —NR2R3, —S(O)mNR2R3, —NR4(C1-C4alkanoyl) and —CONR2R3, or R is 2,3-dihydrobenzo[b]furanyl or chromanyl; R1is H or C1-C6alkyl; W is a direct link, methylene or ethylene; X is unbranched C2-C4alkylene; Y is phenyl, naphthyl, benzyl, pyridyl, thienyl or C3-C7cycloalkyl, each of which being optionally substituted by from 1 to 3 substituents each independently selected from C1-C4alkyl, fluoro(C1-C4)alkyl, C1-C4alkoxy, fluoro(C1-C4)alkoxy, halo and cyano; Ar is phenyl, naphthyl, benzyl, thienyl, benzo[b]thienyl or indolyl, each of which being optionally substituted by from 1 to 3 substituents each independently selected from C1-C4alkyl, fluoro(C1-C4)alkyl, C1-C4alkoxy, fluoro(C1-C4)alkoxy, halo and cyano, or Ar is 1,3-benzodioxolan-4 or 5-yl or 1,4-benzodioxan-5 or 6-yl; ZAis a pharmaceutically acceptable anion; with the proviso that when W is a direct link and R is optionally fused and optionally substituted heteroaryl, said heteroaryl is linked by a ring carbon atom to the carbonyl group. The compounds are tachykinin antagonists.

The anomalous stille reaction of 5-stannylimidazole with 3-iodoindole

Palladium(0)-catalyzed cross-coupling reaction of 5-stannylimidazole with 3-iodoindole gave two products including unexpected cine substitution.